Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
61
resultados
Última actualización
26/11/2025 [06:45:00]
Resultados 25 a 50 de 61
Resumen de: WO2025231380A1
Proteolysis-targeting chimeras (PROTACs) that indirectly inhibit Myeloid Cell Leukemia-1 (Mcl-1) oncoprotein, and methods of using the same, are provided for treating disease.
Resumen de: US2025339429A1
The present disclosure provides methods for treating ULK3-associated cancers, such as multiple myeloma or breast cancer, in subjects in need thereof.
Resumen de: US2025339527A1
Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.
Resumen de: US2025339426A1
Provided herein are methods of treating advanced solid tumors in a subject in need thereof, for example, when the subject has advanced squamous cell carcinoma of the head and neck, colorectal cancer, non-small cell lung cancer, and transitional cell carcinoma of the bladder. Also provided herein are methods of treating blood cancers, such as acute myeloid leukemia, in a subject in need thereof.
Resumen de: WO2025231449A1
The present disclosure provides improved compositions and methods for detecting, diagnosing, prognosing, monitoring, and treating hematological disorders including multiple myeloma in a subject. In particular, the disclosure provides methods for detecting IL4I1 in subjects to reliably diagnose, predict survival, or monitor multiple myeloma in the subject and methods for inhibiting IL4I1 to treat multiple myeloma in the subject.
Resumen de: WO2025230982A1
The present disclosure provides compounds of Formula (IA) and (IIA). The disclosure also provides methods of using compounds of Formula (IA), (IIA), and (I)-(X). The present disclosure further provides for methods of treating lymphoma and methods of treating autoimmune disorders. Also disclosed herein are methods of inhibiting a Pleckstrin Homology (PH) domain of Interleukin-2 (IL-2) inducible T-cell kinase.
Resumen de: US2025339503A1
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular of hematological neoplasms, such as acute myeloid leukemia (AML). The present invention furthermore relates to tumor-associated T-cell peptide epitopes that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Resumen de: WO2025231299A1
The present disclosure relates to HA-1-targeted T cell receptor (TCR) T cell therapy for treating hematological cancer, such as recurrent leukemia after hematopoietic stem cell transplantation. Provided embodiments include T cell compositions and methods of using the same in therapy, as well as methods of making the compositions. Provided embodiments further include CD8+ T cells made by a method and methods for making CD8+ T cells.
Resumen de: US2025339406A1
Provided herein are small molecule inhibitors of NSD1, NSD2 and/or NSD3 activity, and methods of use thereof for the treatment of disease, including leukemia, breast cancer, osteosarcoma, lung and prostate cancers and other solid tumors as well as other diseases dependent on the activity of NSD1, NSD2 and/or NSD3.
Resumen de: WO2025229179A1
The present invention relates to the combination of a compound of formula (I) as described herein with an hypomethylating agent (HMA) for use for the prevention and/ or treatment of cancer, in particular acute myeloid leukemia (AML), and AML-related myeloid diseases. The present invention further relates to a pharmaceutical composition comprising a compound of formula (I) as described herein with an HMA.
Resumen de: WO2025231408A2
Provided herein are methods of treating cancer in a subject in need thereof by administering an anti-BCMA CAR-T cell and a GPRC5DxCD3 bispecific antibody. In some embodiments, the subject has relapsed and/or refractory multiple myeloma. In some embodiments, the subject has received at least one prior line of therapy. In some embodiments, the subject has newly diagnosed multiple myeloma and is transplant ineligible.
Resumen de: WO2025230946A1
Disclosed herein is a platform technology for designing T cell engagers. Examples of such T cell engagers and nucleic acids (e.g., mRNAs) encoding same as well as lipid nanoparticles comprising nucleic acids (e.g., mRNAs) encoding the T cell engagers are provided. Such T cell engagers can be used to treat cancers such as FCRH5+, GPRC5D+, and/or BCMA+ cancers, including hematological malignancies such as multiple myeloma (e.g., advanced MM, RRMM), B cell lymphoma, and myeloid cancers.
Resumen de: WO2025231372A2
Provided herein are methods of treating cancer in a subject in need thereof. In some embodiments, the method comprises administering an anti-BCMA CAR-T cell and a GPRC5DxCD3 bispecific antibody. In some embodiments, the method comprises administering an anti-BMCA CAR-T cell, a GPRC5DxCD3 bispecific antibody, and a BCMAxCD3 bispecific antibody.
Resumen de: EP4643952A2
Disclosed are methods for inhibiting proliferation of or inducing apoptosis in certain leukemia cells or both. The methods comprise contacting a leukemia cell exhibiting an NPM1 mutation with a pharmacologic inhibitor of interaction between MLL and menin. More broadly, disclosed are methods for treating a susceptible leukemia using pharmacologic inhibition of Menin-MLL interaction. Also disclosed are methods for treating such leukemias using inhibition of Menin-MLL interaction in combination with DOT1L inhibition.
Resumen de: MX2025011928A
The invention comprises a new and inventive method for conjugating the L-asparaginase enzyme with polyethylene glycol molecules, preferably polyethylene glycol maleimide (PEG-Mal), via cysteine residues present on the surface of the molecule. In addition, the invention relates to the product obtained from this method and the use of the PEG-conjugated enzyme in the treatment of different types of neoplasia, such as acute lymphoid leukaemia.
Resumen de: MX2025012452A
The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancers that overexpress the histone methyltransferase WHSC1, e.g., t(4;14) multiple myeloma, by administering to a subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.
Resumen de: MX2025012388A
The present invention relates to combinations comprising a therapeutically effective amount of a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor; and a therapeutically effective amount of a DNA intercalating agent and a pyrimidine analog; as well as to methods for treating a subject diagnosed with cancer using such combinations.
Resumen de: MX2025008887A
Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I), (II), or (III)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the inventive IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.
Resumen de: MX2025012028A
The present invention provides dosing regimens of bispecific antibodies targeting both CD3 and CD20 when used in the treatment of lymphoma, such as B-cell Non-Hodgkin lymphoma (B-NHL).
Resumen de: MX2025009619A
The present invention provides therapeutics for the treatment of CCR9-positive cancers such as T-cell acute lymphoblastic leukemia. In particular, the present invention provides a CCR9 targeting moiety. The present invention furthermore relates to a CCR9 targeting moiety comprising a further targeting moiety, preferably a CD1a targeting moiety, a dual CAR comprising a CCR9 and a CD1a targeting moiety, their use in the treatment of CCR9 and/or CD1a positive cancers, and the use of a CCR9 targeting moiety and a separate CD1a targeting moiety for such treatment.
Resumen de: NZ751414A
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody MOR00208 and a BCL-2 inhibitor venetoclax for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
Resumen de: US2025333502A1
Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, acute leukemia cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is desirable. In other embodiments the circulating cells are leukemia cells, particularly acute myeloid leukemia (AML), where increased phagocytosis is desirable.
Resumen de: US2025333445A1
The invention provides a CD16a-binding polypeptide which comprises at least one motif that binds to CD16a, wherein said polypeptide comprises the following structure: N-terminal portion-Helix 1-Separating portion-Helix 2-C-terminal portion the CD16a-binding motif being the portion Helix 1-Separating portion-Helix 2. The invention further provides pharmaceutical compositions comprising the CD16a-binding polypeptide, and the use of the CD16a-binding polypeptide or pharmaceutical compositions as a medicament, particularly for use in the treatment or prophylaxis of cancers such as multiple myeloma.
Nº publicación: US2025332216A1 30/10/2025
Solicitante:
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC [CN]
IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC
Resumen de: US2025332216A1
A method of treating classic Hodgkin's lymphoma (cHL) in a subject in need thereof, comprising intravenously administering to the subject i) a recombinant fusion protein at the dose of about 2.0 mg/kg body weight, once a week, and ii) an anti-PD-1 antibody at the dose of about 200 mg, once every 3 weeks, wherein the recombinant fusion protein comprises a mutated SIRPα D1 domain and a functional IgG1 heavy chain constant region, wherein the mutated SIRPα D1 domain comprises the amino acid sequence of SEQ ID NO: 2.
BOPI
Sede Electrónica
